| Risperdal Consta Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Risperdal Consta 25 mg/2 weeks | powder for injection, extended release | intramuscular | 1.0 each | OTC |
| Risperdal Consta 37.5 mg/2 weeks | powder for injection, extended release | intramuscular | 1.0 each | OTC |
| Risperdal Consta 50 mg/2 weeks | powder for injection, extended release | intramuscular | 1.0 each | OTC |
Study finds IONSYS (TM), a New Needle-Free System for Management ... - ITNews
... behavioural psychological symptoms of dementia, disruptive behaviour disorders, autism) and RISPERDAL(R), CONSTA(TM) (schizophrenia). ...
Tue Mar 04 01:02:18 -0500 2008
Study finds IONSYS (TM), a New Needle-Free System for Management ... - ITNews
... behavioural psychological symptoms of dementia, disruptive behaviour disorders, autism) and RISPERDAL(R), CONSTA(TM) (schizophrenia). ...
Tue Mar 04 01:02:18 -0500 2008
FDA rejects injectable Zyprexa - Indianapolis Star
That version of the drug, Risperdal Consta, is manufactured by Alkermes and already has achieved blockbuster status by exceeding $1.1 billion in annual ...
Fri Feb 29 02:50:26 -0500 2008
risperidone - A benzisoxazole derivative with antipsychotic property. Risperidone selectively antagonizes serotonin (5-HT) effects via cortical 5-HT2 receptor, and, to a lesser extent, competes with dopamine at the limbic dopamine D2 receptor. The antagonism leads to decreased psychotic effects, such as hallucinations and delusions. In addition, risperidone has low to moderate affinity for histamine H1, 5-HT1A, 5-HT1C, and 5-HT1D receptors, while it has weak affinity for dopamine D1 and haloperidol-sensitive sigma site receptors.